{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:33:42Z","timestamp":1790127222497,"version":"4.0.1"},"reference-count":308,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Opioid misuse and opioid-involved overdose deaths are a massive public health problem involving the intertwined misuse of prescription opioids for pain management with the emergence of extremely potent fentanyl derivatives, sold as standalone products or adulterants in counterfeit prescription opioids or heroin. The incidence of repeated opioid overdose events indicates a problematic use pattern consistent with the development of the medical condition of opioid use disorder (<jats:bold>OUD<\/jats:bold>). Prescription and illicit opioids reduce pain perception by activating \u00b5-opioid receptors (<jats:bold>MOR<\/jats:bold>) localized to the central nervous system (<jats:bold>CNS<\/jats:bold>). Dysregulation of meso-corticolimbic circuitry that subserves reward and adaptive behaviors is fundamentally involved in the progressive behavioral changes that promote and are consequent to OUD. Although opioid-induced analgesia and the rewarding effects of abused opioids are primarily mediated through MOR activation, serotonin (<jats:bold>5-HT<\/jats:bold>) is an important contributor to the pharmacology of opioid abused drugs (including heroin and prescription opioids) and OUD. There is a recent resurgence of interest into psychedelic compounds that act primarily through the 5-HT<jats:sub>2A<\/jats:sub> receptor (<jats:bold>5-HT<\/jats:bold><jats:sub><jats:bold>2A<\/jats:bold><\/jats:sub><jats:bold>R<\/jats:bold>) as a new frontier in combatting such diseases (e.g., depression, anxiety, and substance use disorders). Emerging data suggest that the MOR and 5-HT<jats:sub>2A<\/jats:sub>R crosstalk at the cellular level and within key nodes of OUD circuitry, highlighting a major opportunity for novel pharmacological intervention for OUD. There is an important gap in the preclinical profiling of psychedelic 5-HT<jats:sub>2A<\/jats:sub>R agonists in OUD models. Further, as these molecules carry risks, additional analyses of the profiles of non-hallucinogenic 5-HT<jats:sub>2A<\/jats:sub>R agonists and\/or 5-HT<jats:sub>2A<\/jats:sub>R positive allosteric modulators may provide a new pathway for 5-HT<jats:sub>2A<\/jats:sub>R therapeutics. In this review, we discuss the opportunities and challenges associated with utilizing 5-HT<jats:sub>2A<\/jats:sub>R agonists as therapeutics for OUD.<\/jats:p>","DOI":"10.3389\/fphar.2023.1239159","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T06:47:53Z","timestamp":1697006873000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["\u03bc-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges"],"prefix":"10.3389","volume":"14","author":[{"given":"Leah M.","family":"Salinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina R.","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana L.","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle C.","family":"Anastasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"B1","unstructured":"Provisional drug overdose death counts\n            AhmadF. B.\n            CisewskiJ. A.\n            RossenL. M.\n            SuttonP.\n          2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.pain.2012.03.017","article-title":"Selective impairment of spinal mu-opioid receptor mechanism by plasticity of serotonergic facilitation mediated by 5-HT2A and 5-HT2B receptors","volume":"153","author":"Aira","year":"2012","journal-title":"Pain"},{"key":"B3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/cercor\/bhg128","article-title":"Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex","volume":"14","author":"Amargos-Bosch","year":"2004","journal-title":"Cereb. Cortex."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1021\/acschemneuro.5b00094","article-title":"Serotonin (5-HT) 5-HT2A receptor (5-HT2AR):5-HT2CR imbalance in medial prefrontal cortex associates with motor impulsivity","volume":"6","author":"Anastasio","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"B5","first-page":"959","article-title":"The use of drug discrimination procedures to characterize hallucinogenic drug actions","volume":"22","author":"Appel","year":"1986","journal-title":"Psychopharmacol. Bull."},{"key":"B6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0149-7634(82)90036-7","article-title":"Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures","volume":"6","author":"Appel","year":"1982","journal-title":"Neurosci. Biobehav Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/0024-3205(89)90278-6","article-title":"Identification of fatty acid amides in human plasma","volume":"45","author":"Arafat","year":"1989","journal-title":"Life Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"103518","DOI":"10.1016\/j.drugpo.2021.103518","article-title":"Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting","volume":"100","author":"Argento","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/7854_2017_476","article-title":"Hallucinogens in drug discrimination","volume":"36","author":"Baker","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.22122\/ahj.v13i1.290","article-title":"The role of impulsivity and sensitivity to reward in dropout of addiction treatment in heroin addicts","volume":"13","author":"Bakhshipour-Rudsari","year":"2021","journal-title":"Addict. Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.tins.2016.03.004","article-title":"Prefrontal cortical opioids and dysregulated motivation: A network hypothesis","volume":"39","author":"Baldo","year":"2016","journal-title":"Trends Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1124\/pr.118.015552","article-title":"International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function","volume":"73","author":"Barnes","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3928\/00485713-20220804-01","article-title":"Psychedelics in the treatment of substance use disorders","volume":"52","author":"Barnett","year":"2022","journal-title":"Psychiatr. Ann."},{"key":"B15","doi-asserted-by":"publisher","first-page":"846589","DOI":"10.1155\/2015\/846589","article-title":"Genotype-dependent difference in 5-HT2C receptor-induced hypolocomotion: Comparison with 5-HT2A receptor functional activity","volume":"2015","author":"Bazovkina","year":"2015","journal-title":"Neural Plast."},{"key":"B16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1037\/1064-1297.12.3.163","article-title":"Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys","volume":"12","author":"Beardsley","year":"2004","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ejpain.2007.12.007","article-title":"Signal valence in the nucleus accumbens to pain onset and offset","volume":"12","author":"Becerra","year":"2008","journal-title":"Eur. J. Pain"},{"key":"B18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ijnp\/pyac075","article-title":"Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants","volume":"26","author":"Becker","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B19","article-title":"Animal models of drug addiction","volume-title":"Addictions","author":"Belin-Rauscent","year":"2012"},{"key":"B20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archneurpsyc.1956.02330290012002","article-title":"Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication","volume":"76","author":"Belleville","year":"1956","journal-title":"AMA Arch. Neurol. Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e45146","DOI":"10.7554\/eLife.45146","article-title":"Synapse-specific opioid modulation of thalamo-cortico-striatal circuits","volume":"8","author":"Birdsong","year":"2019","journal-title":"Elife"},{"key":"B22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0006-8993(88)90172-2","article-title":"Correspondence between 5-HT2 receptors and serotonergic axons in rat neocortex","volume":"453","author":"Blue","year":"1988","journal-title":"Brain Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1073\/pnas.95.8.4102","article-title":"Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide","volume":"95","author":"Boger","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/7854_2016_10","article-title":"Human drug discrimination: elucidating the neuropharmacology of commonly abused illicit drugs","volume":"39","author":"Bolin","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/j.1471-4159.2005.03485.x","article-title":"The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity","volume":"95","author":"Bortolozzi","year":"2005","journal-title":"J. Neurochem."},{"key":"B26","first-page":"145","article-title":"Traditional healing practices involving psychoactive plants and the global mental health agenda: Opportunities, pitfalls, and challenges in the \"Right to Science\" framework","volume":"22","author":"Bouso","year":"2020","journal-title":"Health Hum. Rights"},{"key":"B27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1176\/appi.ajp.20220312","article-title":"Risk of experiencing an overdose event for patients undergoing treatment with medication for opioid use disorder","volume":"180","author":"Brandt","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/00003495-199040060-00010","article-title":"Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease","volume":"40","author":"Brogden","year":"1990","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41386-018-0271-x","article-title":"Dorsal raphe serotonin neurons inhibit operant responding for reward via inputs to the ventral tegmental area but not the nucleus accumbens: evidence from studies combining optogenetic stimulation and serotonin reuptake inhibition","volume":"44","author":"Browne","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1200\/EDBK_208563","article-title":"Pain management in the era of the opioid crisis","volume":"38","author":"Bruera","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bbr.2014.12.014","article-title":"Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites","volume":"281","author":"Buchborn","year":"2015","journal-title":"Behav. Brain Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.bbr.2012.11.030","article-title":"Antagonizing 5-HT\u2082A receptors with M100907 and stimulating 5-HT\u2082C receptors with Ro60-0175 blocks cocaine-induced locomotion and zif268 mRNA expression in Sprague-Dawley rats","volume":"240","author":"Burton","year":"2013","journal-title":"Behav. Brain Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tins.2012.05.005","article-title":"\u03ba-opioid receptor\/dynorphin system: genetic and pharmacotherapeutic implications for addiction","volume":"35","author":"Butelman","year":"2012","journal-title":"Trends Neurosci."},{"key":"B34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/B978-0-12-420172-9.00010-2","article-title":"Regulatory framework and guidance to the evaluation of the abuse liability of drugs in the United States and Europe","volume-title":"Nonclinical assessment of abuse potential for new pharmaceuticals","author":"Calderon","year":"2015"},{"key":"B35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mcna.2021.08.010","article-title":"Understanding stimulant use and use disorders in a new era","volume":"106","author":"Ciccarone","year":"2022","journal-title":"Med. Clin. North Am."},{"key":"B36","doi-asserted-by":"publisher","first-page":"109352","DOI":"10.1016\/j.neuropharm.2022.109352","article-title":"Considerations in assessing the abuse potential of psychedelics during drug development","volume":"224","author":"Calderon","year":"2023","journal-title":"Neuropharmacology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF02245782","article-title":"Differentiation between the stimulus effects of (+)-lysergic acid diethylamide and lisuride using a three-choice, drug discrimination procedure","volume":"100","author":"Callahan","year":"1990","journal-title":"Psychopharmacology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/pme.12773","article-title":"Pharmaceutical opioid use and dependence among people living with chronic pain: Associations observed within the pain and opioids in treatment (POINT) cohort","volume":"16","author":"Campbell","year":"2015","journal-title":"Pain Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neuropharm.2013.01.007","article-title":"Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model","volume":"70","author":"Canal","year":"2013","journal-title":"Neuropharmacology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.abl8615","article-title":"Structure-based discovery of nonhallucinogenic psychedelic analogs","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/1096-9861(20000918)425:2<275::aid-cne9>3.0.co;2-z","article-title":"Dopamine terminals synapse on callosal projection neurons in the rat prefrontal cortex","volume":"425","author":"Carr","year":"2000","journal-title":"J. Comp. Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2009.04.003","article-title":"Principles of laboratory assessment of drug abuse liability and implications for clinical development","volume":"105","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"B44","doi-asserted-by":"publisher","first-page":"115028","DOI":"10.1016\/j.bcp.2022.115028","article-title":"Selective\" serotonin 5-HT2A receptor antagonists","volume":"200","author":"Casey","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/rapm-2020-101273","article-title":"Chronic pain and psychedelics: a review and proposed mechanism of action","volume":"45","author":"Castellanos","year":"2020","journal-title":"Reg. Anesth. Pain Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/brain\/awac366","article-title":"Common and distinct fronto-striatal volumetric changes in heroin and cocaine use disorders","volume":"146","author":"Ceceli","year":"2023","journal-title":"Brain"},{"key":"B47","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/s0028-3908(98)00208-1","article-title":"Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors","volume":"38","author":"Cheer","year":"1999","journal-title":"Neuropharmacology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1021\/acs.jmedchem.3c00908","article-title":"Discovery of novel oleamide analogues as brain-penetrant positive allosteric serotonin 5-HT2C receptor and dual 5-HT2C\/5-HT2A receptor modulators","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jsat.2019.07.005","article-title":"Buprenorphine in the United States: Motives for abuse, misuse, and diversion","volume":"104","author":"Chilcoat","year":"2019","journal-title":"J. Subst. Abuse Treat."},{"key":"B50","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/mdc3.12466","article-title":"The relationship between serotonin-2A receptor and cognitive functions in nondemented Parkinson's disease patients with visual hallucinations","volume":"4","author":"Cho","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"B51","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/bjp.2008.100","article-title":"Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction","volume":"154","author":"Christie","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"B52","first-page":"633","article-title":"Cellular mechanisms of opioid tolerance: studies in single brain neurons","volume":"32","author":"Christie","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.pharmthera.2013.06.003","article-title":"Delta opioid receptors in brain function and diseases","volume":"140","author":"Chu Sin Chung","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.biopsych.2019.05.012","article-title":"The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: A review of the evidence","volume":"86","author":"Clark","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.pain.2012.07.035","article-title":"Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations","volume":"153","author":"Comer","year":"2012","journal-title":"Pain"},{"key":"B56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00401509","article-title":"A possible correlation between drug-induced hallucinations in man and a behavioural response in mice","volume":"11","author":"Corne","year":"1967","journal-title":"Psychopharmacologia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1476-5381.1963.tb01302.x","article-title":"A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine","volume":"20","author":"Corne","year":"1963","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1124\/jpet.119.259408","article-title":"The opioid crisis and the future of addiction and pain therapeutics","volume":"371","author":"Coussens","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1126\/science.7770779","article-title":"Chemical characterization of a family of brain lipids that induce sleep","volume":"268","author":"Cravatt","year":"1995","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1021\/cn300072u","article-title":"Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction","volume":"4","author":"Cunningham","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.neuropharm.2013.06.030","article-title":"Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction","author":"Cunningham","year":"2014","journal-title":"Neuropharmacology"},{"key":"B62","first-page":"217","article-title":"Hallucinogenic and non-hallucinogenic 5-HT agonists: Differences in subjective effects parallel differences in receptor dynamics","volume-title":"5-HT agonists as psychoactive drugs","author":"Cunningham","year":"1988"},{"key":"B63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF00690929","article-title":"Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD)","volume":"91","author":"Cunningham","year":"1987","journal-title":"Psychopharmacol. Berl."},{"key":"B64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0014-2999(85)90723-x","article-title":"Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD","volume":"108","author":"Cunningham","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"B65","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/B978-0-444-64125-0.00040-2","article-title":"Serotonin neurobiology in cocaine use disorder","volume-title":"Handbook of the behavioral neurobiology of serotonin","author":"Cunningham","year":"2020"},{"key":"B66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/acschemneuro.2c00597","article-title":"Pharmacological mechanism of the non-hallucinogenic 5-HT(2A) agonist ariadne and analogs","volume":"14","author":"Cunningham","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1080\/14656566.2021.1942455","article-title":"Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication","volume":"22","author":"Davis","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/acschemneuro.0c00291","article-title":"Psychedelic-like properties of quipazine and its structural analogues in mice","volume":"12","author":"De La Fuente Revenga","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e213059","DOI":"10.1001\/jamanetworkopen.2021.3059","article-title":"Pharmaceutical opioid use patterns and indicators of extramedical use and harm in adults with chronic noncancer pain, 2012-2018","volume":"4","author":"Degenhardt","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B70","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1021\/cn300020x","article-title":"Exploration of synthetic approaches and pharmacological evaluation of PNU-69176E and its stereoisomer as 5-HT2C receptor allosteric modulators","volume":"3","author":"Ding","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"9791","DOI":"10.1007\/s11033-020-06009-x","article-title":"Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review","volume":"47","author":"Divito","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.cell.2021.03.043","article-title":"Psychedelic-inspired drug discovery using an engineered biosensor","volume":"184","author":"Dong","year":"2021","journal-title":"Cell"},{"key":"B73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/02791072.2019.1606472","article-title":"The past and future of psychedelic science: An introduction to this issue","volume":"51","author":"Doblin","year":"2019","journal-title":"J. Psychoact. Drugs"},{"key":"B74","doi-asserted-by":"publisher","first-page":"0487","DOI":"10.1523\/ENEURO.0487-21.2022","article-title":"The contributions of mu-opioid receptors on glutamatergic and GABAergic neurons to analgesia induced by various stress intensities","volume":"9","author":"Du","year":"2022","journal-title":"eNeuro"},{"key":"B75","doi-asserted-by":"publisher","first-page":"113612","DOI":"10.1016\/j.biopha.2022.113612","article-title":"Serotonin 5-HT2A, 5-HT2C and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response","volume":"154","author":"Erkizia-Santamaria","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.bbi.2020.03.003","article-title":"Fentanyl self-administration impacts brain immune responses in male Sprague-Dawley rats","volume":"87","author":"Ezeomah","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"B77","unstructured":"Public meeting on patient-focused drug development for opioid use disorder (Voice of the Patient)2018"},{"key":"B78","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00008877-200403000-00007","article-title":"Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys","volume":"15","author":"Fantegrossi","year":"","journal-title":"Behav. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/sj.npp.1300442","article-title":"Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys","volume":"29","author":"Fantegrossi","year":"","journal-title":"Neuropsychopharmacology"},{"key":"B80","volume-title":"Assessment of abuse potential of drugs: guidance for industry","author":"Fda","year":"2017"},{"key":"B81","first-page":"332","article-title":"Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems","volume":"299","author":"Fedorova","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e0203137","DOI":"10.1371\/journal.pone.0203137","article-title":"Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interaction","volume":"13","author":"Felsing","year":"2018","journal-title":"PLoS One"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/cercor\/bhl104","article-title":"Extensive overlap of mu-opioid and nicotinic sensitivity in cortical interneurons","volume":"17","author":"Ferezou","year":"2007","journal-title":"Cereb. Cortex"},{"key":"B84","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.tins.2015.01.002","article-title":"Understanding opioid reward","volume":"38","author":"Fields","year":"2015","journal-title":"Trends Neurosci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/npp.2015.46","article-title":"Individual differences in impulsive action reflect variation in the cortical serotonin 5-HT2A receptor system","volume":"40","author":"Fink","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF02246075","article-title":"Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: Reassessment of LSD false positives","volume":"121","author":"Fiorella","year":"","journal-title":"Psychopharmacol. Berl."},{"key":"B87","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/BF02246074","article-title":"The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis","volume":"121","author":"Fiorella","year":"","journal-title":"Psychopharmacol. Berl."},{"key":"B88","first-page":"75","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"108599","DOI":"10.1016\/j.drugalcdep.2021.108599","article-title":"Discriminative stimulus effects of carfentanil in rats discriminating fentanyl: Differential antagonism by naltrexone","volume":"221","author":"Flynn","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"B90","doi-asserted-by":"publisher","first-page":"540423","DOI":"10.3389\/fpubh.2020.540423","article-title":"The opioid\/overdose crisis as a dialectics of pain, despair, and one-sided struggle","volume":"8","author":"Friedman","year":"2020","journal-title":"Front. Public Health"},{"key":"B91","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1476-5381.1954.tb00848.x","article-title":"Drugs which antagonize 5-hydroxytryptamine","volume":"9","author":"Gaddum","year":"1954","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"B92","doi-asserted-by":"publisher","first-page":"9575","DOI":"10.1021\/acs.jmedchem.7b00994","article-title":"A positive allosteric modulator of the serotonin 5-HT(2C) receptor for obesity","volume":"60","author":"Garcia-Carceles","year":"2017","journal-title":"J. Med. Chem."},{"key":"B93","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey","volume":"10","author":"Garcia-Romeu","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B94","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/178210a0","article-title":"Prevention of psychological effects of d-lysergic acid diethylamide (LSD 25) by its 2-brom derivative (BOL 148)","volume":"178","author":"Ginzel","year":"1956","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/0091-3057(93)90379-8","article-title":"MDMA-like stimulus effects of alpha-ethyltryptamine and the alpha-ethyl homolog of DOM","volume":"46","author":"Glennon","year":"1993","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/0006-2952(83)90281-2","article-title":"Indolealkylamine and phenalkylamine hallucinogens. Effect of alpha-methyl and N-methyl substituents on behavioral activity","volume":"32","author":"Glennon","year":"1983","journal-title":"Biochem. Pharmacol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonzalez-Maeso","year":"2007","journal-title":"Neuron"},{"key":"B98","doi-asserted-by":"publisher","first-page":"8836","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003","article-title":"Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex","volume":"23","author":"Gonzalez-Maeso","year":"2003","journal-title":"J. Neurosci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.vascn.2016.07.004","article-title":"An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates","volume":"82","author":"Goodwin","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B100","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/scientificamerican1210-76","article-title":"Hallucinogens as medicine","volume":"303","author":"Griffiths","year":"2010","journal-title":"Sci. Am."},{"key":"B101","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.3390\/ijerph18115749","article-title":"Prospective Study on Factors Associated with Referral of Patients with Opioid Maintenance Therapy from Specialized Addictive Disorders Centers to Primary Care","volume":"18","author":"Guillou-Landreat","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","article-title":"On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis","volume":"39","author":"Hacksell","year":"2014","journal-title":"Neurochem. Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"107933","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00213-009-1718-x","article-title":"LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor","volume":"208","author":"Halberstadt","year":"2010","journal-title":"Psychopharmacol. Berl."},{"key":"B105","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0893-133X(00)00184-6","article-title":"Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal","volume":"24","author":"Harris","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1176\/appi.ajp.2013.12060782","article-title":"DSM-5 criteria for substance use disorders: recommendations and rationale","volume":"170","author":"Hasin","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"B107","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1176\/appi.ajp.21070721","article-title":"Diagnosing prescription opioid use disorder in patients using prescribed opioids for chronic pain","volume":"179","author":"Hasin","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"B108","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","article-title":"Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans","volume":"142","author":"Heal","year":"2018","journal-title":"Neuropharmacology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/s0006-2952(99)00274-9","article-title":"Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors","volume":"58","author":"Hedlund","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1073\/pnas.0337340100","article-title":"No hypothermic response to serotonin in 5-HT7 receptor knockout mice","volume":"100","author":"Hedlund","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B111","doi-asserted-by":"publisher","first-page":"17448069211043965","DOI":"10.1177\/17448069211043965","article-title":"A systematic review on descending serotonergic projections and modulation of spinal nociception in chronic neuropathic pain and after spinal cord stimulation","volume":"17","author":"Heijmans","year":"2021","journal-title":"Mol. Pain"},{"key":"B112","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/psymed.2023.0009","article-title":"Tabernanthalog reduces motivation for heroin and alcohol in a polydrug use model","volume":"1","author":"Heinsbroek","year":"2023","journal-title":"Psychedelic Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/psymed.2022.0003","article-title":"Past, Present, and Future of Psychedelics: A Psychedelic Medicine Roundtable Discussion","volume":"1","author":"Hendricks","year":"2023","journal-title":"Psychedelic Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"109220","DOI":"10.1016\/j.neuropharm.2022.109220","article-title":"Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling","volume":"218","author":"Henningfield","year":"2022","journal-title":"Neuropharmacology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1014768","DOI":"10.3389\/fnsys.2022.1014768","article-title":"Endogenous opioid systems alterations in pain and opioid use disorder","volume":"16","author":"Higginbotham","year":"2022","journal-title":"Front. Syst. Neurosci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"107417","DOI":"10.1016\/j.pharmthera.2019.107417","article-title":"Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential","volume":"205","author":"Higgins","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41594-017-0011-7","article-title":"Structure and dynamics of GPCR signaling complexes","volume":"25","author":"Hilger","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"711255","DOI":"10.3389\/fphar.2021.711255","article-title":"Role of the 5-HT(2A) receptor in acute effects of LSD on empathy and circulating oxytocin","volume":"12","author":"Holze","year":"","journal-title":"Front. Pharmacol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"","journal-title":"Neuropsychopharmacology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov. Disord."},{"key":"B121","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/pr.114.009514","article-title":"Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder","volume":"67","author":"Howell","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"B122","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(21)02252-2","article-title":"Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission","volume":"399","author":"Humphreys","year":"2022","journal-title":"Lancet"},{"key":"B123","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/jamapsychiatry.2022.5159","article-title":"Twenty-Year Trends in Drug Overdose Fatalities Among Older Adults in the US","volume":"80","author":"Humphreys","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"B124","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease--it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1124\/mol.64.1.78","article-title":"Positive allosteric modulator of the human 5-HT2C receptor","volume":"64","author":"Im","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"e202875","DOI":"10.1001\/jamanetworkopen.2020.2875","article-title":"Assessment of potentially inappropriate prescribing of opioid analgesics requiring prior opioid tolerance","volume":"3","author":"Jeffery","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B127","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1057563029001\/4881","article-title":"Extraction studies of Tabernanthe iboga and Voacanga africana","volume":"16","author":"Jenks","year":"2002","journal-title":"Nat. Prod. Lett."},{"key":"B128","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1038\/s41598-022-06580-2","article-title":"Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"key":"B130","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1038\/s41598-022-08085-4","article-title":"Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"key":"B131","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/FBP.0b013e3283641c3d","article-title":"A review of human drug self-administration procedures","volume":"24","author":"Jones","year":"2013","journal-title":"Behav. Pharmacol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1177\/0333102410363490","article-title":"The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series","volume":"30","author":"Karst","year":"2010","journal-title":"Cephalalgia"},{"key":"B133","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1213\/00000539-196405000-00013","article-title":"Study of lysergic acid diethylamide as an analgesic agent","volume":"43","author":"Kast","year":"1964","journal-title":"Anesth. Analgesia"},{"key":"B134","first-page":"968","article-title":"Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile","volume":"277","author":"Kehne","year":"1996","journal-title":"J.Pharmacol Exp.Ther."},{"key":"B135","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cub.2007.12.057","article-title":"Morphine-induced receptor endocytosis in a novel knockin mouse reduces tolerance and dependence","volume":"18","author":"Kim","year":"2008","journal-title":"Curr. Biol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","article-title":"Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor","volume":"182","author":"Kim","year":"2020","journal-title":"Cell"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.pain.2011.04.020","article-title":"Contribution of afferent pathways to nerve injury-induced spontaneous pain and evoked hypersensitivity","volume":"152","author":"King","year":"2011","journal-title":"Pain"},{"key":"B138","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1369-1600.2012.00447.x","article-title":"Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk","volume":"19","author":"Koenig","year":"2014","journal-title":"Addict. Biol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"J. Neurosci."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/nn1105-1442","article-title":"Plasticity of reward neurocircuitry and the 'dark side' of drug addiction","volume":"8","author":"Koob","year":"2005","journal-title":"Nat. Neurosci."},{"key":"B141","first-page":"481","article-title":"Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat","volume":"229","author":"Koob","year":"1984","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B142","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: A neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"B143","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s40429-021-00401-8","article-title":"Novel treatment approaches for substance use disorders: Therapeutic use of psychedelics and the role of psychotherapy","volume":"9","author":"Koslowski","year":"2021","journal-title":"Curr. Addict. Rep."},{"key":"B144","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0893-133X(97)00164-4","article-title":"Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors","volume":"18","author":"Krebs-Thomson","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"B145","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00213-006-0566-1","article-title":"The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats","volume":"189","author":"Krebs-Thomson","year":"2006","journal-title":"Psychopharmacol. Berl."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1210\/en.2007-1321","article-title":"Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors","volume":"149","author":"Lam","year":"2008","journal-title":"Endocrinology"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","article-title":"Reward processing by the opioid system in the brain","volume":"89","author":"Le Merrer","year":"2009","journal-title":"Physiol. Rev."},{"key":"B148","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.drugalcdep.2009.02.007","article-title":"Risk management of drug products and the U.S. Food and Drug Administration: evolution and context","volume":"105","author":"Leiderman","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/schbul\/sbaa117","article-title":"Hallucinations under psychedelics and in the schizophrenia spectrum: An interdisciplinary and multiscale comparison","volume":"46","author":"Leptourgos","year":"2020","journal-title":"Schizophr. Bull."},{"key":"B150","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.pbb.2005.08.008","article-title":"Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats","volume":"82","author":"Leri","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B151","doi-asserted-by":"publisher","first-page":"112203","DOI":"10.1016\/j.celrep.2023.112203","article-title":"A non-hallucinogenic LSD analog with therapeutic potential for mood disorders","volume":"42","author":"Lewis","year":"2023","journal-title":"Cell Rep."},{"key":"B152","doi-asserted-by":"publisher","first-page":"797217","DOI":"10.3389\/fnbeh.2021.797217","article-title":"Blockade of 5-hydroxytryptamine 2A receptor attenuates precipitation of naloxone-induced withdrawal symptoms in opioid-exposed mice","volume":"15","author":"Li","year":"2021","journal-title":"Front. Behav. Neurosci."},{"key":"B153","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/npp.2010.232","article-title":"Effects of direct- and indirect-acting serotonin receptor agonists on the antinociceptive and discriminative stimulus effects of morphine in rhesus monkeys","volume":"36","author":"Li","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"B154","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1021\/acs.chemrev.5b00656","article-title":"Practical strategies and concepts in GPCR allosteric modulator discovery: Recent advances with metabotropic glutamate receptors","volume":"116","author":"Lindsley","year":"2016","journal-title":"Chem. Rev."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.neuron.2014.02.010","article-title":"Dorsal raphe neurons signal reward through 5-HT and glutamate","volume":"81","author":"Liu","year":"2014","journal-title":"Neuron"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1124\/mol.108.048272","article-title":"Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation","volume":"74","author":"Lopez-Gimenez","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/1096-9861(20010122)429:4<571::aid-cne5>3.0.co;2-x","article-title":"Mapping of 5-HT2A receptors and their mRNA in monkey brain: [3H]MDL100,907 autoradiography and in situ hybridization studies","volume":"429","author":"Lopez-Gimenez","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"B159","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pbb.2004.12.002","article-title":"A preclinical comparison between different opioids: antinociceptive versus adverse effects","volume":"80","author":"Meert","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B160","doi-asserted-by":"publisher","first-page":"110977","DOI":"10.1016\/j.pscychresns.2019.08.005","article-title":"Cingulo-hippocampal effective connectivity positively correlates with drug-cue attentional bias in opioid use disorder","volume":"294","author":"Ma","year":"2019","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"B161","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1037\/\/1064-1297.5.3.256","article-title":"Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: drug and monetary rewards","volume":"5","author":"Madden","year":"1997","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"B163","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/jpet.122.001318","article-title":"Effects of 2,5-dimethoxy-4-methylamphetamine (DOM) and 2-piperazin-1-yl-quinoline (quipazine) on fentanyl versus food choice in rhesus monkeys","volume":"384","author":"Maguire","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B164","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00213-012-2803-0","article-title":"Effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys","volume":"225","author":"Maguire","year":"2013","journal-title":"Psychopharmacol. Berl."},{"key":"B165","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0166-2236(95)93946-u","article-title":"Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications","volume":"18","author":"Mansour","year":"1995","journal-title":"Trends Neurosci."},{"key":"B166","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/0166-2236(88)90093-8","article-title":"Anatomy of CNS opioid receptors","volume":"11","author":"Mansour","year":"1988","journal-title":"Trends Neurosci."},{"key":"B167","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/s0306-4522(98)00043-8","article-title":"5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by mu-opiate receptor activation","volume":"86","author":"Marek","year":"1998","journal-title":"Neuroscience"},{"key":"B168","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s0014-2999(03)01971-x","article-title":"Behavioral evidence for mu-opioid and 5-HT2A receptor interactions","volume":"474","author":"Marek","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1124\/jpet.119.262477","article-title":"Translating pharmacology into therapeutics to fight the opioid crisis","volume":"371","author":"Marek","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B170","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00213-002-1141-z","article-title":"Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats","volume":"164","author":"Marona-Lewicka","year":"2002","journal-title":"Psychopharmacol. Berl."},{"key":"B171","doi-asserted-by":"publisher","first-page":"e12926","DOI":"10.1111\/adb.12926","article-title":"Effects of 5-HT2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats","volume":"26","author":"Martin","year":"2021","journal-title":"Addict. Biol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1177\/0269881116641331","article-title":"Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents","volume":"30","author":"Mash","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fphar.2018.00529","article-title":"Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes","volume":"9","author":"Mash","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"106620","DOI":"10.1016\/j.phrs.2022.106620","article-title":"IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy","volume":"190","author":"Mash","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B175","doi-asserted-by":"publisher","first-page":"PL45","DOI":"10.1016\/0024-3205(95)00273-9","article-title":"Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin","volume":"57","author":"Mash","year":"","journal-title":"Life Sci."},{"key":"B176","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0304-3940(95)11608-y","article-title":"Properties of ibogaine and its principal metabolite (12- hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex","volume":"192","author":"Mash","year":"","journal-title":"Neurosci. Lett."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/add.12181","article-title":"A critique of Minozzi et al.'s pain relief and dependence systematic review","volume":"108","author":"Mcauliffe","year":"2013","journal-title":"Addiction"},{"key":"B178","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","article-title":"The promises and perils of psychedelic pharmacology for psychiatry","volume":"21","author":"Mcclure-Begley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B179","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.drugalcdep.2015.04.001","article-title":"The rise (and fall?) of drug discrimination research","volume":"151","author":"Mcmahon","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"B180","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"B181","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neulet.2019.05.033","article-title":"CB1R mediates oleamide's reward while 5HT2cR mediates aversion in the nucleus accumbens shell of rats","volume":"706","author":"Mendez-Diaz","year":"2019","journal-title":"Neurosci. Lett."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1022863","DOI":"10.3389\/fphar.2022.1022863","article-title":"Heightened cocaine-seeking in male rats associates with a distinct transcriptomic profile in the medial prefrontal cortex","volume":"13","author":"Merritt","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0306-4522(02)00580-8","article-title":"Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex","volume":"116","author":"Miner","year":"2003","journal-title":"Neuroscience"},{"key":"B184","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1360-0443.2012.04005.x","article-title":"Development of dependence following treatment with opioid analgesics for pain relief: a systematic review","volume":"108","author":"Minozzi","year":"2013","journal-title":"Addiction"},{"key":"B185","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuropharm.2013.10.021","article-title":"Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action","volume":"79","author":"Mocci","year":"2014","journal-title":"Neuropharmacology"},{"key":"B186","doi-asserted-by":"publisher","first-page":"249","DOI":"10.15412\/J.BCN.03070310","article-title":"5-HT2A serotonin receptor density in adult male rats' hippocampus after morphine-based conditioned place preference","volume":"7","author":"Mohammadi","year":"2016","journal-title":"Basic Clin. Neurosci."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat. Neurosci."},{"key":"B188","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1901\/jeab.1958.1-103","article-title":"Some factors involved in the stimulus control of operant behavior","volume":"1","author":"Morse","year":"1958","journal-title":"J. Exp. Anal. Behav."},{"key":"B189","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.1074\/jbc.M117.779041","article-title":"Heterodimers of serotonin receptor subtypes 2 are driven by 5-HT2C protomers","volume":"292","author":"Moutkine","year":"2017","journal-title":"J. Biol. Chem."},{"key":"B190","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/ijms21062160","article-title":"The Role of Dorsal Raphe Serotonin Neurons in the Balance between Reward and Aversion","volume":"21","author":"Nagai","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B191","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ejpain.2010.04.008","article-title":"5-HT2C receptor agonists attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain","volume":"14","author":"Nakai","year":"2010","journal-title":"Eur. J. Pain"},{"key":"B192","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.schres.2019.02.018","article-title":"Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist","volume":"208","author":"Nasrallah","year":"2019","journal-title":"Schizophr. Res."},{"key":"B193","doi-asserted-by":"publisher","first-page":"20709","DOI":"10.1073\/pnas.1214605109","article-title":"Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry","volume":"109","author":"Navratilova","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1021\/acschemneuro.6b00413","article-title":"Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats","volume":"8","author":"Neelakantan","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"B195","first-page":"1245","article-title":"Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats","volume":"265","author":"Negus","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/pl00005315","article-title":"Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors","volume":"359","author":"Nelson","year":"1999","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"B198","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1055\/a-1310-3990","article-title":"The history of psychedelics in psychiatry","volume":"54","author":"Nichols","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"B199","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0166-4328(85)90090-7","article-title":"Antagonism of the LSD cue by putative serotonin antagonists: relationship to inhibition of in vivo [3H]spiroperidol binding","volume":"16","author":"Nielsen","year":"1985","journal-title":"Behav. Brain Res."},{"key":"B200","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","article-title":"Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study","volume":"44","author":"Noller","year":"2018","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"B201","doi-asserted-by":"publisher","first-page":"350","DOI":"10.31887\/DCNS.2009.11.3\/cpobrien","article-title":"Neuroplasticity in addictive disorders","volume":"11","author":"O'brien","year":"2009","journal-title":"Dialogues Clin. Neurosci."},{"key":"B202","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.neubiorev.2010.10.012","article-title":"The predictive validity of the rat self-administration model for abuse liability","volume":"35","author":"O'connor","year":"2011","journal-title":"Neurosci. Biobehav Rev."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s43440-021-00248-w","article-title":"5-HT2A receptor- and M1 muscarinic acetylcholine receptor-mediated activation of G\u03b1q\/11 in postmortem dorsolateral prefrontal cortex of opiate addicts","volume":"73","author":"Odagaki","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"B204","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1744-8069-7-4","article-title":"Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents","volume":"7","author":"Okun","year":"2011","journal-title":"Mol. Pain"},{"key":"B205","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects","volume":"4","author":"Olson","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B206","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1021\/acs.jmedchem.8b00403","article-title":"Synthesis and evaluation of a novel bivalent selective antagonist for the mu-delta opioid receptor heterodimer that reduces morphine withdrawal in mice","volume":"61","author":"Olson","year":"2018","journal-title":"J. Med. Chem."},{"key":"B207","doi-asserted-by":"publisher","first-page":"217","DOI":"10.18203\/2319-2003.ijbcp20170312","article-title":"The pathophysiological role of serotonin receptor systems in opioid analgesia and tolerance","volume":"6","author":"Ozdemir","year":"2017","journal-title":"Int. J. Basic & Clin. Pharmacol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1007\/BF02245008","article-title":"Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function","volume":"112","author":"Palfreyman","year":"1993","journal-title":"Psychopharmacol. Berl."},{"key":"B209","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fphar.2016.00514","article-title":"Blockade of serotonin 5-HT2A receptors suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-treated mice","volume":"7","author":"Pang","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/sj.npp.1300599","article-title":"Human cocaine-seeking behavior and its control by drug-associated stimuli in the laboratory","volume":"30","author":"Panlilio","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"B211","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/s0278-5846(01)00268-8","article-title":"Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine","volume":"26","author":"Parke","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B212","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1037\/pha0000507","article-title":"Examining associations between impulsivity, opioid use disorder, and posttraumatic stress disorder: The additive relation between disorders","volume":"30","author":"Peck","year":"2022","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.npp.1300819","article-title":"Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex","volume":"31","author":"Pehek","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"B214","first-page":"1009","article-title":"Discriminative stimulus effects of the mixed-opioid agonist\/antagonist dezocine: cross-substitution by mu and delta opioid agonists","volume":"283","author":"Picker","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B215","doi-asserted-by":"publisher","first-page":"109906","DOI":"10.1016\/j.cellsig.2020.109906","article-title":"Signaling diversity of mu- and delta-opioid receptor ligands: Re-evaluating the benefits of beta-arrestin\/G protein signaling bias","volume":"80","author":"Pineyro","year":"2021","journal-title":"Cell Signal"},{"key":"B216","doi-asserted-by":"publisher","first-page":"8825","DOI":"10.1523\/JNEUROSCI.0133-14.2014","article-title":"Endogenous opioid-induced neuroplasticity of dopaminergic neurons in the ventral tegmental area influences natural and opiate reward","volume":"34","author":"Pitchers","year":"2014","journal-title":"J. Neurosci."},{"key":"B217","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/syn.21592","article-title":"5-HT(2A) receptor blockade and 5-HT(2C) receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamen","volume":"66","author":"Pockros","year":"2012","journal-title":"Synapse"},{"key":"B218","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1017\/S0033291719002393","article-title":"LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making","volume":"50","author":"Pokorny","year":"2020","journal-title":"Psychol. Med."},{"key":"B219","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0169-328x(94)90223-2","article-title":"Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors","volume":"23","author":"Pompeiano","year":"1994","journal-title":"Brain Res. Mol. Brain Res."},{"key":"B220","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/sj.bjp.0702751","article-title":"Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells","volume":"128","author":"Porter","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1073\/pnas.1815129116","article-title":"Effective connectivity changes in LSD-induced altered states of consciousness in humans","volume":"116","author":"Preller","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B223","article-title":"Prescription of controlled substances: Benefits and risks","volume-title":"StatPearls","author":"Preuss","year":"2023"},{"key":"B224","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1021\/acschemneuro.8b00669","article-title":"Endogenous serotonin 5-HT(2A) and 5-HT(2C) receptors associate in the medial prefrontal cortex","volume":"10","author":"Price","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"B225","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.neubiorev.2016.10.005","article-title":"Endocannabinoids and sleep","volume":"71","author":"Prospero-Garcia","year":"2016","journal-title":"Neurosci. Biobehav Rev."},{"key":"B226","first-page":"425","article-title":"Neuroplasticity mechanisms in the pathophysiology of chronic pain","volume":"51","author":"Puretic","year":"2012","journal-title":"Acta Clin. Croat."},{"key":"B227","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/npp.2011.228","article-title":"Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers","volume":"37","author":"Quednow","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B228","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fnmol.2020.00052","article-title":"The delta-opioid receptor; a target for the treatment of pain","volume":"13","author":"Quirion","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00405570","article-title":"Observations on direct and cross tolerance with LSD and d-amphetamine in man","volume":"5","author":"Rosenberg","year":"1963","journal-title":"Psychopharmacologia"},{"key":"B230","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","article-title":"NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted","volume":"44","author":"Rasmussen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"B232","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"key":"B233","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B234","doi-asserted-by":"publisher","first-page":"307106","DOI":"10.1155\/2014\/307106","article-title":"Pharmacology of hallucinations: several mechanisms for one single symptom?","volume":"2014","author":"Rolland","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"B235","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1517\/14740330902931524","article-title":"Serotonergic drugs and valvular heart disease","volume":"8","author":"Rothman","year":"2009","journal-title":"Expert Opin. Drug Saf."},{"key":"B236","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/BF00441948","article-title":"Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis","volume":"98","author":"Sadzot","year":"1989","journal-title":"Psychopharmacol. Berl."},{"key":"B237","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1037\/pha0000253","article-title":"Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats","volume":"27","author":"Sakloth","year":"2019","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"B238","article-title":"Substance Abuse and Mental Health Services Administration","volume-title":"Key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health","year":"2021"},{"key":"B239","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb. Cortex"},{"key":"B240","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jpain.2020.12.008","article-title":"Serotonin plays a key role in the development of opioid-induced hyperalgesia in mice","volume":"22","author":"Sasaki","year":"2021","journal-title":"J. Pain"},{"key":"B241","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study","volume":"28","author":"Savage","year":"1973","journal-title":"Arch. Gen. Psychiatry"},{"key":"B242","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/0006-3223(86)90053-3","article-title":"Influence of environmental context on tolerance to LSD-induced behavior in primates","volume":"21","author":"Schlemmer","year":"1986","journal-title":"Biol. Psychiatry"},{"key":"B243","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/0024-3205(95)00210-w","article-title":"The role of 5-HT2A receptors in antipsychotic activity","volume":"56","author":"Schmidt","year":"1995","journal-title":"Life Sci."},{"key":"B244","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2019.01.020","article-title":"Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats","volume":"150","author":"Schwienteck","year":"2019","journal-title":"Neuropharmacology"},{"key":"B245","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.addbeh.2018.09.020","article-title":"Epidemiology of hallucinogen use in the U.S. results from the national epidemiologic survey on alcohol and related conditions III","volume":"89","author":"Shalit","year":"2019","journal-title":"Addict. Behav."},{"key":"B246","volume-title":"PiHKAL: a chemical love story","author":"Shulgin","year":"1991"},{"key":"B247","doi-asserted-by":"publisher","first-page":"108988","DOI":"10.1016\/j.neuropharm.2022.108988","article-title":"Sex-specific role for serotonin 5-HT(2A) receptor in modulation of opioid-induced antinociception and reward in mice","volume":"209","author":"Sierra","year":"2022","journal-title":"Neuropharmacology"},{"key":"B248","doi-asserted-by":"publisher","first-page":"684720","DOI":"10.3389\/fpsyt.2021.684720","article-title":"The phenomenology and neurobiology of visual distortions and hallucinations in schizophrenia: An update","volume":"12","author":"Silverstein","year":"2021","journal-title":"Front. Psychiatry"},{"key":"B249","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ejmech.2018.12.070","article-title":"Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT(2C) and negative allosteric modulator of 5-HT(2B) receptors","volume":"164","author":"Singh","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"B250","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1358\/mf.2003.25.4.769675","article-title":"Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP\/DA\/serotoninergic pathways","volume":"25","author":"Singh","year":"2003","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"B251","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/jnc.15540","article-title":"Molecular insights into psychedelic drug action","volume":"162","author":"Slocum","year":"2022","journal-title":"J. Neurochem."},{"key":"B252","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00213-002-1252-6","article-title":"Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+\/-)DOI] in C57BL\/6J mice","volume":"166","author":"Smith","year":"2003","journal-title":"Psychopharmacol. Berl."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.neuron.2018.08.044","article-title":"Kappa Opioid Receptor Distribution and Function in Primary Afferents","volume":"99","author":"Snyder","year":"2018","journal-title":"Neuron"},{"key":"B254","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1017\/S1461145710000702","article-title":"Oleamide administered into the nucleus accumbens shell regulates feeding behaviour via CB1 and 5-HT2C receptors","volume":"13","author":"Soria-Gomez","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B255","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3389\/fphar.2019.00907","article-title":"In vivo and in vitro analyses of novel peptidomimetic disruptors for the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog (PTEN)","volume":"10","author":"Soto","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"247","DOI":"10.31887\/DCNS.2017.19.3\/rspanagel","article-title":"Animal models of addiction","volume":"19","author":"Spanagel","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"key":"B257","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.neuron.2018.04.021","article-title":"A genetically encoded biosensor reveals location bias of opioid drug action","volume":"98","author":"Stoeber","year":"2018","journal-title":"Neuron"},{"key":"B258","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40614-022-00330-5","article-title":"A brief introduction to human behavioral pharmacology: Methods, design considerations and ethics","volume":"45","author":"Stoops","year":"2022","journal-title":"Perspect. Behav. Sci."},{"key":"B259","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B260","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00213-005-2192-8","article-title":"A paradigm to investigate the self-regulation of cocaine administration in humans","volume":"180","author":"Sughondhabirom","year":"2005","journal-title":"Psychopharmacol. Berl."},{"key":"B261","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1176\/appi.ajp.20220592","article-title":"Understanding the risks of long-term opioid therapy for chronic pain","volume":"179","author":"Sullivan","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"B262","doi-asserted-by":"publisher","first-page":"2698811231190865","DOI":"10.1177\/02698811231190865","article-title":"The risk of chronic psychedelic and MDMA microdosing for valvular heart disease","author":"Tagen","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s0306-4522(00)00124-x","article-title":"A group of cortical interneurons expressing mu-opioid receptor-like immunoreactivity: a double immunofluorescence study in the rat cerebral cortex","volume":"98","author":"Taki","year":"2000","journal-title":"Neuroscience"},{"key":"B264","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1124\/jpet.102.038133","article-title":"GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system","volume":"303","author":"Tao","year":"","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B265","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/0306-4522(95)00154-b","article-title":"Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain","volume":"68","author":"Tao","year":"1995","journal-title":"Neuroscience"},{"key":"B266","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1124\/jpet.102.037861","article-title":"Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system","volume":"303","author":"Tao","year":"","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B267","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/sj.bjp.0705378","article-title":"Effect of fentanyl on 5-HT efflux involves both opioid and 5-HT1A receptors","volume":"139","author":"Tao","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"B268","first-page":"481","article-title":"Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine","volume":"286","author":"Tao","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B269","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1073\/pnas.84.12.4308","article-title":"Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography","volume":"84","author":"Tempel","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B270","doi-asserted-by":"publisher","first-page":"14115","DOI":"10.1073\/pnas.94.25.14115","article-title":"Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide","volume":"94","author":"Thomas","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B271","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.113.209643","article-title":"Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine","volume":"348","author":"Thurner","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B272","doi-asserted-by":"publisher","first-page":"109018","DOI":"10.1016\/j.drugalcdep.2021.109018","article-title":"Compulsivity and impulsivity in opioid dependence","volume":"229","author":"Tolomeo","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"B273","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugalcdep.2009.10.011","article-title":"The endogenous opioid system: a common substrate in drug addiction","volume":"108","author":"Trigo","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"B274","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1002\/hlca.19570400716","article-title":"Substitutionen am ringsystem der lysergs\u00e4ure. III. Halogenierung. 45. Mitteilung \u00fcber Mutterkornalkaloide","volume":"40","author":"Troxler","year":"1957","journal-title":"Helvetica Chim. Acta"},{"key":"B275","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0006-8993(77)90424-3","article-title":"Usefulness of an animal behavioral model in studying the duration of action of LSD and the onset and duration of tolerance to LSD in the cat","volume":"132","author":"Trulson","year":"1977","journal-title":"Brain Res."},{"key":"B276","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1176\/ajp.116.3.261","article-title":"Chemotherapeutic trials in psychosis. III. Addendum-2-brom-d-lysergic acid diethylamide (BOL)","volume":"116","author":"Turner","year":"1959","journal-title":"Am. J. Psychiatry"},{"key":"B277","doi-asserted-by":"publisher","first-page":"12956","DOI":"10.3390\/ijms222312956","article-title":"Role of nociceptin\/orphanin FQ-NOP receptor system in the regulation of stress-related disorders","volume":"22","author":"Ubaldi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B278","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/biomedicines10010080","article-title":"Alterations in the proteome and phosphoproteome profiles of rat hippocampus after six months of morphine withdrawal: Comparison with the forebrain cortex","volume":"10","author":"Ujcikova","year":"2021","journal-title":"Biomedicines"},{"key":"B279","doi-asserted-by":"publisher","first-page":"1156319","DOI":"10.3389\/fnins.2023.1156319","article-title":"Mini-review: The neurobiology of treating substance use disorders with classical psychedelics","volume":"17","author":"Urban","year":"2023","journal-title":"Front. Neurosci."},{"key":"B280","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1002\/jcph.1923","article-title":"Clinical pharmacology, toxicity, and abuse potential of opioids","volume":"61","author":"Vearrier","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"B281","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/s41386-018-0225-3","article-title":"Untangling the complexity of opioid receptor function","volume":"43","author":"Valentino","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"B282","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropylo xy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol.Exp.Ther."},{"key":"B283","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1017\/S1461145710000349","article-title":"Simultaneous projections from prefrontal cortex to dopaminergic and serotonergic nuclei","volume":"14","author":"Vazquez-Borsetti","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B284","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/cercor\/bhn204","article-title":"Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors","volume":"19","author":"Vazquez-Borsetti","year":"2009","journal-title":"Cereb. Cortex"},{"key":"B285","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/npp.2017.172","article-title":"Compulsive-like sufentanil vapor self-administration in rats","volume":"43","author":"Vendruscolo","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"B286","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0028-3908(80)90131-8","article-title":"Head twitches induced by LSD and quipazine: Similarities and differences","volume":"19","author":"Vetulani","year":"1980","journal-title":"Neuropharmacology"},{"key":"B287","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B288","doi-asserted-by":"publisher","first-page":"325","DOI":"10.7326\/0003-4819-155-5-201109060-00011","article-title":"Long-term opioid therapy reconsidered","volume":"155","author":"Von Korff","year":"2011","journal-title":"Ann. Intern Med."},{"key":"B289","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain"},{"key":"B290","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B291","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.121.000689","article-title":"Antinociceptive and discriminative stimulus effects of six novel psychoactive opioid substances in male rats","volume":"379","author":"Walker","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B292","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1126\/science.7071600","article-title":"Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions","volume":"216","author":"White","year":"1982","journal-title":"Science"},{"key":"B293","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0091-3057(86)90367-9","article-title":"Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions","volume":"24","author":"White","year":"1986","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B294","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1021\/acs.jmedchem.8b00401","article-title":"Design, synthesis, and characterization of 4-undecylpiperidine-2-carboxamides as positive allosteric modulators of the serotonin (5-HT) 5-HT(2C) receptor","volume":"62","author":"Wild","year":"2019","journal-title":"J. Med. Chem."},{"key":"B295","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1152\/physrev.2001.81.1.299","article-title":"Cellular and synaptic adaptations mediating opioid dependence","volume":"81","author":"Williams","year":"2001","journal-title":"Physiol. Rev."},{"key":"B296","first-page":"699","article-title":"Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats","volume":"282","author":"Willins","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B297","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF00432134","article-title":"Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus","volume":"68","author":"Winter","year":"1980","journal-title":"Psychopharmacol. Berl."},{"key":"B298","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1021\/acs.jmedchem.8b00875","article-title":"Allosteric modulation of class A GPCRs: Targets, agents, and emerging concepts","volume":"62","author":"Wold","year":"","journal-title":"J. Med. Chem."},{"key":"B299","doi-asserted-by":"publisher","first-page":"7529","DOI":"10.1021\/acs.jmedchem.9b01953","article-title":"Discovery of 4-phenylpiperidine-2-carboxamide analogues as serotonin 5-HT(2C) receptor-positive allosteric modulators with enhanced drug-like properties","volume":"63","author":"Wold","year":"2020","journal-title":"J. Med. Chem."},{"key":"B300","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2174\/1568026619666190709101449","article-title":"Targeting the 5-HT2C receptor in biological context and the current state of 5-HT2C receptor ligand development","volume":"19","author":"Wold","year":"","journal-title":"Curr. Top. Med. Chem."},{"key":"B301","doi-asserted-by":"publisher","first-page":"109504","DOI":"10.1016\/j.neuropharm.2023.109504","article-title":"Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders","volume":"231","author":"Wulff","year":"2023","journal-title":"Neuropharmacology"},{"key":"B302","doi-asserted-by":"publisher","first-page":"e00403","DOI":"10.1002\/prp2.403","article-title":"Evaluation of morphine-like effects of the mixed mu\/delta agonist morphine-6-O-sulfate in rats: Drug discrimination and physical dependence","volume":"6","author":"Yadlapalli","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"B303","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.neuropharm.2016.07.036","article-title":"Loss of GluN2D subunit results in social recognition deficit, social stress, 5-HT2C receptor dysfunction, and anhedonia in mice","volume":"112","author":"Yamamoto","year":"2017","journal-title":"Neuropharmacology"},{"key":"B304","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fnint.2018.00054","article-title":"The varieties of the psychedelic experience: A preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines","volume":"12","author":"Zamberlan","year":"2018","journal-title":"Front. Integr. Neurosci."},{"key":"B305","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1021\/acs.jmedchem.5b01499","article-title":"Nociceptin opioid receptor (NOP) as a therapeutic target: Progress in translation from preclinical research to clinical utility","volume":"59","author":"Zaveri","year":"2016","journal-title":"J. Med. Chem."},{"key":"B306","doi-asserted-by":"publisher","first-page":"e55289","DOI":"10.7554\/eLife.55289","article-title":"Different neuronal populations mediate inflammatory pain analgesia by exogenous and endogenous opioids","volume":"9","author":"Zhang","year":"2020","journal-title":"Elife"},{"key":"B307","article-title":"Novel heterocyclic compounds as serotonin (5-HT) 5-HT2A and 5-HT2C receptor positive allosteric modulators","author":"Zhou","year":"2023"},{"key":"B308","doi-asserted-by":"publisher","first-page":"109528","DOI":"10.1016\/j.neuropharm.2023.109528","article-title":"Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs","volume":"233","author":"Zia","year":"2023","journal-title":"Neuropharmacology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1239159\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T06:48:24Z","timestamp":1697006904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1239159\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":308,"alternative-id":["10.3389\/fphar.2023.1239159"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1239159","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"article-number":"1239159"}}